OSR Holdings, Inc. operates as a global healthcare company. The company is headquartered in Bellevue, Washington and currently employs 22 full-time employees. The company went IPO on 2023-02-10. Through its subsidiaries, it is engaged in immuno-oncology, regenerative biologics, and medical device technologies. Its operating businesses include developing oral immunotherapies for the treatment of cancer, developing design-augmented (DA) biologics for age-related and other degenerative diseases and neurovascular intervention medical devices and systems distribution in Korea. Its subsidiaries include VAXIMM AG (Vaximm); RMC Co., Ltd. (RMC); Darnatein Co., Ltd. (Darnatein), and Woori IO Co., Ltd. (Woori IO). Vaximm is developing oral immunotherapies for the treatment of cancer and immunological disorders. RMC is a Korea-based neurovascular intervention medical device and systems distribution company. Darnatein is developing DA biologics for age-related and other degenerative diseases. Woori IO is a South Korea-based medical device company.
Loading...
